等待开盘 12-20 09:30:00 美东时间
+0.300
+0.89%
Liquidia Technologies ($LQDA) announced an update on their ongoing clinical stu...
12-18 00:32
今日重点评级关注:瑞银:维持Syndax Pharmaceuticals"买入"评级,目标价从35美元升至38美元;HC Wainwright & Co.:维持Benitec Biopharma"买入"评级,目标价从28美元升至35美元
11-05 10:35
U.S. stocks were lower, with the Nasdaq Composite falling more than 350 points ...
11-05 01:37
BTIG analyst Julian Harrison reiterates Liquidia (NASDAQ:LQDA) with a Buy and maintains $49 price target.
11-04 18:32
Liquidia (NASDAQ:LQDA) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.40) by 90.02 percent. This is a 89.74 percent increase over losses of $(0.39) per share from the same
11-03 19:31
Companies Reporting Before The Bell • CNA Financial (NYSE:CNA) is expected to r...
11-03 19:11
Liquidia Corporation announced that its executive leadership team will provide updates during fireside chats at two investor conferences in November: the 2025 UBS Global Healthcare Conference on November 10 and the Jefferies London Healthcare Conference on November 18. Webcasts of both presentations will be available on Liquidia’s website, with archived versions accessible for 30 days post-event. Liquidia, a biopharmaceutical company, revolutioni...
11-03 13:00
Liquidia Corporation reported third-quarter 2025 financial results, highlighting $51.7 million in net product sales of YUTREPIA™, achieving profitability in its first full quarter of sales. The company saw over 2,000 unique patient prescriptions and 1,500 patient starts. Financials showed a net loss of $3.5 million, improved profitability with $1.7 million in operating income, and $157.5 million in cash equivalents.YUTREPIA's strong launch and gr...
11-03 11:30
Liquidia (NASDAQ:LQDA) is set to give its latest quarterly earnings report on M...
11-01 00:03
今日重点评级关注:Ascendiant Capital:维持PAVmed"买入"评级,目标价从19美元升至20美元;Ascendiant Capital:维持Plus Therapeutics"买入"评级,目标价从20.5美元升至21美元
10-07 15:04